GH31
/ Genhouse Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 16, 2026
Gilead's latest synthetic lethal therapy comes via $1.5B deal with China's Genhouse
(FierceBiotech)
- "The Suzhou-based biotech has been developing the MAT2A-targetting synthetic lethal therapy, dubbed GH31, for various tumor types...As well as the upfront payment, Genhouse will be in line for up to $1.45 billion in milestone payments as well as royalties based on tiered double-digit percentages on net sales."
Licensing / partnership • Solid Tumor
1 to 1
Of
1
Go to page
1